Africa’s regulatory landscape reached a notable milestone in August 2026 when Mozambique achieved WHO ML3 recognition for its national regulatory system, the Autoridade Nacional Reguladora de Medicamentos de Moçambique (ANARME), for medicines and imported vaccines. With this achievement, Mozambique became the 10th African country to reach ML3, joining Egypt, Ethiopia, Ghana, Nigeria, Rwanda, Senegal, South Africa, Tanzania and Zimbabwe.

The significance of this milestone extends beyond the number ten – it signals a broader transformation in how African countries regulate health products and support pharmaceutical sector growth. As countries seek to expand local pharmaceutical manufacturing, attract international investment, strengthen supply-chain resilience and improve preparedness for future health emergencies, regulatory capability is emerging as a critical component of the continent’s healthcare infrastructure.

And now, the question is what can regulatory maturity enable for Africa’s pharmaceutical and healthcare ambitions?

Why Regulatory Maturity Matters?

Strong regulatory systems are essential for ensuring the quality, safety, and efficacy of medicines and vaccines. For patients, a strong regulatory system provides confidence while for manufacturers it creates predictability. A predictable and capable regulator can influence the business environment in which pharmaceutical companies operate. Regulatory maturity also improves investor confidence, supports regional harmonization, and enables reliance-based regulatory approaches. For countries seeking to attract pharmaceutical manufacturing investments, regulatory credibility is increasingly becoming a strategic asset.

Understanding WHO Maturity Levels

The WHO Global Benchmarking Tool (GBT) evaluates national regulatory authorities across functions including marketing authorization, pharmacovigilance, inspections, laboratory testing, licensing, clinical trial oversight, and market surveillance. ML3 denotes a stable, well-functioning, and integrated regulatory system, while ML4 represents an advanced system characterized by continuous improvement.

Africa’s Growing Network of Mature Regulators

As of August 2026, Egypt, Ethiopia, Ghana, Mozambique, Nigeria, Rwanda, Senegal, South Africa, Tanzania, and Zimbabwe have achieved ML3 recognition in one or more regulatory scopes. This expanding network strengthens opportunities for regulatory reliance, regional collaboration, and greater consistency in product oversight across the continent.

The pace of progress is notable. From ‘0’ in 2017 to ‘10’ in 2026, Africa’s regulatory journey is one of progressive strengthening.  Ghana, for instance, moved from ML1 to ML3 over a six-year period. Regulatory maturity status involves multiple assessments and several years of regulatory strengthening supported by an institutional development plan, capacity building and improvements across functions such as pharmacovigilance, market control, marketing authorization and clinical-trial oversight. Zimbabwe moved from an ML1 assessment in 2021 to ML3 in 2024 following implementation of the institutional development plan and corrective actions.

ML3 is therefore an outcome of institutional capability building, not a one-time regulatory event.

Implications for Pharmaceutical Manufacturing

Regulatory maturity can help accelerate product approvals, strengthen GMP oversight, improve post-market surveillance, and facilitate technology transfer partnerships. Manufacturers increasingly consider regulatory capability alongside market size, infrastructure, talent availability, and fiscal incentives when evaluating investment destinations.

The longer-term opportunity lies in connecting markets through regional regulatory harmonization, regulatory reliance, regional economic communities, pooled procurement, continental trade, and the African Medicines Agency (AMA) (AMA African Medicines Agency has become operational, creating a platform for greater regulatory cooperation across countries)

The value of ML3 increases when it becomes part of a broader architecture of regulatory convergence and reliance

The Road from ML3 to ML4 for Mozambique

While achieving ML3 is a significant accomplishment, it is not the endpoint. Countries continue to invest in digitization, quality management systems, workforce development, inspections, and governance mechanisms. Zimbabwe’s progression from ML3 to ML4 demonstrates that African regulatory authorities can continue advancing toward globally recognized regulatory excellence.

Mozambique’s achievement is more than the addition of a tenth country to Africa’s regulatory milestone list. It highlights a continent-wide trend toward stronger, more trusted, and internationally aligned regulatory systems. It is reflective of the high political will and tenacity around the dual goals of a regional value chain for pharma manufacturing in Africa, and the ultimate goal of improved access to quality assured medicines and health products.